Aclarion's Groundbreaking Partnership with Scripps Health
Aclarion, Inc., a healthcare technology innovator, has taken a significant step forward by establishing its first commercial agreement with Scripps Health. This landmark partnership is set to enhance the diagnostic landscape for chronic low back pain across Southern California, benefitting both leading spine physicians and patients.
Access to Nociscan Technology
The agreement allows Scripps Health to utilize Nociscan, Aclarion's cutting-edge technology that combines Magnetic Resonance Spectroscopy (MRS) with augmented intelligence. This fusion provides exceptional insights, helping physicians identify the sources of chronic low back pain more efficiently. With over 3.2 million people residing in the greater San Diego area, this innovative solution will reach a broad audience, ultimately improving patient care.
The Need for Advanced Diagnostics
Chronic low back pain (cLBP) is often difficult to diagnose accurately. Traditional methods can be time-consuming and may not yield definitive results. Dr. Robert Eastlack, an orthopedic surgeon at Scripps Health, highlighted the importance of advanced diagnostic tools like Nociscan. "Having Nociscan available at Scripps Green will greatly expand access to my colleagues and our patients in important ways," he stated. His enthusiasm for transforming diagnostic procedures underlines the significance of this partnership.
The Role of Scripps Health
Scripps Health operates as a nonprofit healthcare system with five hospitals and numerous outpatient facilities in the region. By integrating Nociscan into their services, Scripps aims to provide comprehensive care, reaching thousands of chronic pain patients annually.
Continuing Research and Development
The collaboration also opens doors for ongoing research and clinical trials. With Nociscan's unique capabilities, the physicians at Scripps can delve deeper into understanding chronic pain, allowing for better-targeted treatments. Aclarion's Chief Strategy Officer, Ryan Bond, expressed optimism about the partnership, emphasizing its potential to enhance spine care significantly.
A Clarion Call for Improved Pain Management
Aclarion's vision revolves around addressing global healthcare challenges, particularly in the realm of chronic low back pain. Approximately 266 million individuals worldwide grapple with degenerative spine disease, making innovative solutions like Nociscan critically important. This technology represents a new era of noninvasive diagnostics, providing physicians with essential data to differentiate between painful and non-painful discs in the lumbar spine.
Conclusion: A New Hope for Patients with Chronic Pain
Aclarion's partnership with Scripps Health marks a significant advancement in pain management technology. With Nociscan’s ability to provide objective, evidence-based insights, physicians can enhance their clinical decision-making processes and ultimately, patient outcomes. As this partnership unfolds, many patients suffering from chronic low back pain will gain access to much-needed diagnostic services that have previously been difficult to obtain.
Frequently Asked Questions
What is Nociscan?
Nociscan is an innovative diagnostic platform developed by Aclarion that uses Magnetic Resonance Spectroscopy to help physicians identify sources of chronic low back pain.
How does the partnership with Scripps Health benefit patients?
This partnership expands access to advanced diagnostic technologies for patients suffering from chronic low back pain, leading to improved treatment outcomes.
What is the significance of Aclarion’s technology?
Aclarion's technology allows for noninvasive differentiation of painful and non-painful discs, providing critical insights into patient diagnoses.
Who is Dr. Robert Eastlack?
Dr. Robert Eastlack is an orthopedic surgeon at Scripps Health, recognized for his expertise in spine care and his advocacy for advanced diagnostics.
How prevalent is chronic low back pain globally?
Chronic low back pain affects approximately 266 million people worldwide, making it a considerable public health challenge.
